(Praluzatamab)Biosimilar Reference Antibody-GS40566 新品

货号：GS40566

Praluzatamab is a monoclonal antibody (IgG1 kappa) developed for targeted therapy, primarily in oncology. Its primary mechanism of action is the specific binding to Activated Leukocyte Cell Adhesion Molecule (ALCAM), also known as CD166. While the exact therapeutic modality (e.g., as a naked antibody to block pro-tumorigenic signaling, or as an antibody-drug conjugate/ADC to deliver a cytotoxic payload) would determine its final mechanism, its core function is to specifically recognize and engage ALCAM-expressing cells, potentially inhibiting tumor growth, metastasis, or inducing direct cell death.